This scoping review delineates the evolving evidence landscape surrounding PCV chemotherapy and IDH inhibitors in oligodendrogliomas while underscoring that direct cross-trial comparisons remain difficult due to profound methodological heterogeneity across three decades of research. The gene discussed is IDH1; the disease is oligodendroglioma.